爱美客回应AestheFill销售受限：俪臻厦门代理权获支持 将积极应诉

Core Viewpoint - REGENBiotech, a subsidiary of Aimeike, is currently under a temporary arbitration decision that restricts its ability to sell a specific facial filler product in mainland China and recognizes a local distributor as the exclusive seller [2][3]. Group 1: Arbitration Decision - The Shenzhen International Arbitration Court issued a decision that prohibits REGEN from independently selling the "AestheFill" product in mainland China until the arbitration case is resolved [2]. - The decision confirms that Datou Medical is the exclusive distributor of the product in mainland China and mandates REGEN to continue supplying the product to Datou Medical as per their agreement [2]. - REGEN is not allowed to authorize any third party to sell the product in mainland China and must not provide the product to anyone other than Datou Medical for sales requests [2]. Group 2: Legal Response - Aimeike and REGEN are taking the arbitration matter seriously and have engaged a professional legal team to respond to the situation [3]. - REGEN intends to take all necessary legal actions to modify, suspend, or revoke the temporary measures outlined in the arbitration decision [3]. - The decision is a procedural matter and does not affect the final outcome of the case, which will be determined by the arbitration tribunal [3].